Drugs / ASP7373
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01450579 | Jul → Dec 2011 | — | UMN Pharma Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2012-03-13 | Astellas Pharma Inc | Results Immunogenicity and Favorable Tolerability Observed in Phase II Clinical Trial for H5N1 Influenza Vaccine ASP7373 astellas.com ↗
Astellas and UMN are happy to announce that immunogenicity and favorable tolerability have been observed, and no serious adverse events have been reported. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2012-03-13 | Astellas Pharma Inc | Immunogenicity and Favorable Tolerability Observed in Phase II Clinical Trial for H5N1 Influenza Vaccine ASP7373 astellas.com ↗ |
| 2011-11-11 | Astellas Pharma Inc | Administration of H5N1 Influenza Vaccine ASP7373 Completed in Phase II Clinical Trial astellas.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP7373 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01450579 ↗ |